Search

Your search keyword '"Akay, Olga Meltem"' showing total 316 results
Start Over Author "Akay, Olga Meltem"
316 results on '"Akay, Olga Meltem"'

1. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

Author

Dal, Mehmet Sinan, Ulu, Bahar Uncu, Uzay, Ant, Akay, Olga Meltem, Beşışık, Sevgi, Yenerel, Mustafa Nuri, Çelik, Serhat, Kaynar, Leylagül, Yücel, Orhan Kemal, Deveci, Burak, Sönmez, Mehmet, Mehtap, Özgür, Beköz, Hüseyin Saffet, Sunu, Cenk, Salim, Ozan, Ulaş, Turgay, Kartı, Sami, Altuntaş, Fevzi, Ferhanoğlu, Burhan, and Tuğlular, Tülin Fırat

Published
2023
Full Text
View/download PDF

2. CD5 as a prognostic marker in patients with diffuse large B-cell lymphoma: a multicenter study

Author

Demirci, Ufuk, Kırkızlar, Hakkı Onur, Ümit, Elif G., Gürsoy, Vildan, Pınar, İbrahim Ethem, Özkalemkaş, Fahir, Güven, Zeynep Tuğba, Kaynar, Leylagül, Keklik Karadağ, Fatma, Saydam, Güray, Ekinci, Ömer, Merter, Mustafa, Aras, Merih Reis, Albayrak, Murat, Gülsaran, Sedanur Karaman, Baş, Volkan, Aydın, Berrin Balık, Beköz, Hüseyin Saffet, Can, Ferda, Dilek, İmdat, Mehtap, Özgür, Öztürk, Erman, Çöbanoğlu Şimşek, Bengü, Yıldırım, Murat, Aylı, Meltem, Ataş, Ünal, Salim, Ozan, Ayer, Mesut, Birtaş Ateşoğlu, Elif, Akay, Olga Meltem, Kurt Yüksel, Meltem, Paydaş, Semra, Korkmaz, Selçuk, Öz Puyan, Fulya, and Demir, Ahmet Muzaffer

Published
2022
Full Text
View/download PDF

3. A global assessment of hemostatic function of healthy allogeneic stem cell donors undergoing apheresis by rotational thromboelastometry.

Author

Cilek, Neslihan, Ugurel, Elif, Eren, Ozgur Can, Yalcin, Ozlem, and Akay, Olga Meltem

Subjects
STEM cell donors, GRANULOCYTE-colony stimulating factor, STEM cell transplantation, FUNCTIONAL assessment, THROMBELASTOGRAPHY, HEMAPHERESIS, FILGRASTIM
Abstract

Introduction: Peripheral blood stem cell (PBSC) collection via apheresis requires the administration of granulocyte colony‐stimulating factor (filgrastim) to stem cell donors. Several reports have shown that filgrastim administration and apheresis procedure induce a hypercoagulable state across PBSC collection, which might predispose certain donors to thrombotic complications. Methods: We evaluated the hemostatic functions of healthy allogeneic stem cell donors by rotational thromboelastometry (ROTEM). Blood samples from healthy donors (n = 30) were collected at defined time points: before filgrastim (baseline), on the day of apheresis before and after the procedure, and 1 week after apheresis. Results: The results indicated that hemostatic changes are temporary since all parameters in both EXTEM and INTEM assays are restored to their initial values 1 week after the apheresis. Conclusion: We concluded that stem cell apheresis does not induce a hypercoagulable state in healthy donors. This is the first study evaluating the hemostatic functions of stem cell donors by ROTEM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Increased platelet-leucocyte complexes do not result in coagulation activation in plateletpheresis donors.

Author

Tastekin, Fatih, Akay, Olga Meltem, Colak, Ertugrul, and Gunduz, Eren

Subjects
*BLOOD platelet activation, *FLOW cytometry, *PROTHROMBIN, *FIBRINOLYSIS, *BLOOD coagulation
Abstract

Although plateletpheresis donation is commonly accepted as a safe procedure, its influence on platelet function, coagulation system and fibrinolysis is not completely elucidated.In this study, we tried to assess the effects of plateletpheresis on donor’s hemostasis system by measuring platelet activation, development of platelet-leukocyte aggregates, and coagulation activation.Prospective observational study.We used flow cytometry to determine the levels of platelet-monocyte complexes (PMC) and platelet-neutrophil complexes (PNC). sP-selectin and prothrombin fragment (PF) 1 + 2 values were determined by ELISA.The PMC levels increased significantly seven days after apheresis in comparison with just after apheresis and 24 h after apheresis (p < 0.05). The PNC levels increased significantly seven days after apheresis compared to immediately after apheresis (p < 0.05). sP-selectin values decreased significantly immediately after apheresis (p < 0.05). While sP-selectin values increased seven days after apheresis in comparison with immediately after apheresis and 24 h after apheresis, but there were not statistically significant differences for sP-selectin levels (p > 0.05). PF1 + 2 levels decreased significantly immediately after apheresis compared to pre-apheresis (p < 0.05) and increased 24 h after apheresis and seven days after apheresis, but these differences were not statistically significant.We concluded that plateletpheresis affects platelet activation but does not cause any change in coagulation activation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Clinical characteristics and therapeutic outcomes of paroxysmal nocturnal hemoglobinuria patients in Turkey: a multicenter experience

Author

Goren Sahin, Deniz, Akay, Olga Meltem, Keklik, Muzaffer, Okan, Vahap, Karakus, Abdullah, Demir, Cengiz, Erkurt, Mehmet Ali, Ilkkilic, Kadir, Yildirim, Rahsan, Akgun Cagliyan, Gulsum, Aksu, Salih, Dogu, Mehmet Hilmi, Dal, Mehmet Sinan, Karakus, Volkan, Gemici, Ali Ihsan, Terzi, Hatice, Kelkitli, Engin, Sivgin, Serdar, Unal, Ali, Yilmaz, Mehmet, Ayyildiz, Orhan, Korkmaz, Serdal, Eser, Bulent, and Altuntas, Fevzi

Published
2021
Full Text
View/download PDF

7. Study for the diagnostic screening of paroxsymal nocturnal hemoglobinuria in Turkey: Prospective multicentric evaluation of suspected patients

Author

Ilhan, Osman, Ozdemir, Zehra Narli, Ozet, Gulsum, Falay, Mesude, Yenerel, Mustafa, Tuglular, Tulin, Turgut, Mehmet, Guvenc, Birol, Unal, Ali, Ayyıldız, Orhan, Andic, Neslihan, Hacıhanefioglu, Abdullah, Sahin, Fahri, Sencan, Mehmet, Ali, Ridvan, Ozsan, Guner Hayri, Yildirim, Rahsan, Tiftik, Eyup Naci, Tombak, Anıl, Salim, Ozan, Kaya, Emin, Akay, Olga Meltem, Okan, Vahap, Pehlivan, Mustafa, and Saydam, Guray

Published
2019
Full Text
View/download PDF

8. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Author

Abildgaard, Niels, Adler, Howard, Altuntas, Fevzi, Akay, Olga Meltem, Amin, Bipinkumar, Anagnostopoulos, Achilleas, Anderson, Larry, Anttila, Pekka, Araujo, Carla, Arce-Lara, Carlos, Aydin, Yildiz, Basu, Supratik, Battini, Ramakrishna, Beeker, Thaddeus, Benboubker, Lotfi, Ben-Yehuda, Dina, Bladé, Joan, Blau, Igor Wolfgang, Boccia, Ralph, Burke, Lillian, Byeff, Peter, Cascavilla, Nicola, Cavo, Michele, Chantry, Andrew, Charles, Yen, Chaudhry, Arvind, Corso, Alessandro, Coyne, Mark, De Arriba, Felipe, Delimpasi, Sosana, Desjardins, Pierre, Dhakal, Binod, Di Bartolomeo, Paolo, Di Raimondo, Francesco, Dürig, Jan, Engelhardt, Monika, Escoffre-Barbe, Martine, Esteves, Graca, Flogegard, Max, Gabrail, Nashat, Gamberi, Barbara, Garrison, Mitchell, Gay, Julie, Gisslinger, Heinz, Goldschmidt, Hartmut, Goncalves, Cristina, Gressot, Laurent, Grosicki, Sebastian, Hanna, Wahid, Hayden, Patrick, Henriques Bernardo, Maria Manuela, Hermann, Robert, Holden, Viran, Honkalehto, Kirsti, Huben, Marianne, Huffman, John, Hunter, Hannah, Hus, Marek, Jagasia, Madan, Jagganath, Sundar, Janakiram, Murali, Jaiyesimi, Ishmael, Jenner, Matthew, João, Cristina, Johnson, Peter, Jurcyszyn, Artur, Kalayoğlu Beşişik, Sevgi, Kambhampati, Suman, Kanate, Abraham, Karadoğan, Ihsan, Khojasteh, Ali, Kirkel, Dean, Komarnicki, Mieczyslaw, Krauth, Maria-Theresa, Kuriakose, Phillip, Larocca, Alessandra, Lauri, Birgitta, Leleu, Xavier, Lucio, Paulo, Luppi, Mario, Mangiacavalli, Silvia, Mariette, Clara, Matsue, Kosei, Mellqvist, Ulf-Henri, Mendeleeva, Larisa, Meshad, Michael, Miller, Carole, Mohrbacher, Ann, Moreau, Philippe, Morelli, Anna Maria, Müldür, Ercan, Naassan, Anthony, Nahi, Hareth, Nair, Rajesh, O'Dwyer, Mike, Öngören Aydin, Seniz, Openshaw, Thomas, O'Rourke, Timothy, Osswald, Michael, Overton, Lindsay, Pati, Asmin, Pavic, Michel, Pegourie, Brigitte, Pehlivan, Mustafa, Pierola, Ana Alfonso, Plesner, Torben, Pluta, Andrzej, Rabin, Neil, Ramasamy, Karthik, Rambaldi, Alessandro, Rodriguez, Paula, Röllig, Christoph, Rosenblatt, Jacalyn, Rosenbluth, Jonathan, Salomo, Morten, Samoylova, Olga, Sastre Moral, Jose, Sati, Hamdi, Selleri, Carmine, Shafeek, Salim, Shinagawa, Atsushi, Sleckman, Bethany, Smith, Clay, Sonmez, Mehmet, Stone, Chester, Streetly, Matthew, Suzuki, Kenshi, Taetle, Raymond, Tafuri, Agostino, Takezako, Naoki, Teke, Hava Üsküdar, Vapaatalo, Mirja, Vassilopoulos, George, Verma, Amit, Vidito, Sarah, Viterbo, Luisa, Vural, Filiz, Wang, Xiang Sean, Yağci, Munci, Yee, Andrew, Richardson, Paul G, Oriol, Albert, Beksac, Meral, Liberati, Anna Marina, Galli, Monica, Schjesvold, Fredrik, Lindsay, Jindriska, Weisel, Katja, White, Darrell, Facon, Thierry, San Miguel, Jesus, Sunami, Kazutaka, O'Gorman, Peter, Sonneveld, Pieter, Robak, Pawel, Semochkin, Sergey, Schey, Steve, Yu, Xin, Doerr, Thomas, Bensmaine, Amine, Biyukov, Tsvetan, Peluso, Teresa, Zaki, Mohamed, Anderson, Kenneth, and Dimopoulos, Meletios

Published
2019
Full Text
View/download PDF

11. Glofitamab in relapsed/refractory diffuse large B‐cell lymphoma: Real‐world data

Author

Birtas Atesoglu, Elif, primary, Gulbas, Zafer, additional, Uzay, Ant, additional, Ozcan, Muhit, additional, Ozkalemkas, Fahir, additional, Dal, Mehmet Sinan, additional, Kalyon, Hakan, additional, Akay, Olga Meltem, additional, Deveci, Burak, additional, Bekoz, Huseyin, additional, Sevindik, Omur Gokmen, additional, Toptas, Tayfur, additional, Yilmaz, Fergun, additional, Koyun, Derya, additional, Alkis, Nihan, additional, Alacacioglu, Inci, additional, Sonmez, Mehmet, additional, Yavasoglu, Irfan, additional, Tombak, Anil, additional, Mehtap, Ozgur, additional, Kurnaz, Fatih, additional, Yuce, Orhan Kemal, additional, Karakus, Volkan, additional, Turgut, Mehmet, additional, Kurekci, Derya Deniz, additional, Ayer, Mesut, additional, Keklik, Muzaffer, additional, Buyuktas, Deram, additional, Ozbalak, Murat, additional, and Ferhanoglu, Burhan, additional

Published
2023
Full Text
View/download PDF

16. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab era

Author

Vassilakopoulos, Theodoros P., primary, Panitsas, Fotios, additional, Mellios, Zois, additional, Apostolidis, John, additional, Michael, Michalis, additional, Gurion, Ronit, additional, Ferhanoglu, Burhan, additional, Hatzimichael, Eleftheria, additional, Karakatsanis, Stamatios, additional, Dimou, Maria, additional, Kalpadakis, Christina, additional, Katodritou, Eirini, additional, Leonidopoulou, Theoni, additional, Kotsianidis, Ioannis, additional, Giatra, Hara, additional, Kanellias, Nick, additional, Sayyed, Ayman, additional, Tadmor, Tamar, additional, Akay, Olga Meltem, additional, Angelopoulou, Maria K., additional, Horowitz, Netanel, additional, Bakiri, Maria, additional, Pangalis, Gerassimos A., additional, Panayiotidis, Panayiotis, additional, and Papageorgiou, Sotirios G., additional

Published
2022
Full Text
View/download PDF

17. The Impact of Cytogenetic Aberrations in the Clonal Evolution of Chronic Myeloid Leukemia: A Single-Center Experience Among 450 Turkish Patients (Cohort Study)

Author

Işık, Sevgi, primary, Günden, Gülçin, additional, Üsküdar Teke, Hava, additional, Akay, Olga Meltem, additional, Oğuz Davutoğlu, Nur, additional, Aslan, Vahap, additional, Karagülle, Mustafa, additional, Özen, Hülya, additional, Çilingir, Oğuz, additional, Artan, Sevilhan, additional, and Durak Aras, Beyhan, additional

Published
2022
Full Text
View/download PDF

18. Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

Author

Dal, Mehmet Sinan, primary, Ulu, Bahar Uncu, additional, Uzay, Ant, additional, Akay, Olga Meltem, additional, Beşışık, Sevgi, additional, Yenerel, Mustafa Nuri, additional, Çelik, Serhat, additional, Kaynar, Leylagül, additional, Yücel, Orhan Kemal, additional, Deveci, Burak, additional, Sönmez, Mehmet, additional, Mehtap, Özgür, additional, Beköz, Hüseyin Saffet, additional, Sunu, Cenk, additional, Salim, Ozan, additional, Ulaş, Turgay, additional, Kartı, Sami, additional, Altuntaş, Fevzi, additional, Ferhanoğlu, Burhan, additional, and Tuğlular, Tülin Fırat, additional

Published
2022
Full Text
View/download PDF

19. Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma: Real World Data

Author

Ferhanoglu, Burhan, primary, Gulbas, Zafer, additional, Uzay, Ant, additional, Özcan, Muhit, additional, Ozkalemkas, Fahir, additional, Dal, Mehmet Sinan, additional, Kalyon, Hakan, additional, Akay, Olga Meltem, additional, Deveci, Burak, additional, Bekoz, Huseyin, additional, Sevindik, Omur Gokmen, additional, Toptas, Tayfur, additional, Yilmaz, Asu Fergun, additional, Koyun, Derya, additional, Alkis, Nihan, additional, and Birtas Atesoglu, Elif, additional

Published
2022
Full Text
View/download PDF

24. Incidence and risk factors for central nervous system relapse in patients with primary mediastinal large B‐cell lymphoma in the rituximab era.

Author

Vassilakopoulos, Theodoros P., Panitsas, Fotios, Mellios, Zois, Apostolidis, John, Michael, Michalis, Gurion, Ronit, Ferhanoglu, Burhan, Hatzimichael, Eleftheria, Karakatsanis, Stamatios, Dimou, Maria, Kalpadakis, Christina, Katodritou, Eirini, Leonidopoulou, Theoni, Kotsianidis, Ioannis, Giatra, Hara, Kanellias, Nick, Sayyed, Ayman, Tadmor, Tamar, Akay, Olga Meltem, and Angelopoulou, Maria K.

Subjects
CENTRAL nervous system, DISEASE relapse, RITUXIMAB, INDUCTION chemotherapy, LYMPHOMAS
Abstract

Central nervous system (CNS) involvement is rare in primary mediastinal large B‐cell lymphoma (PMLBCL). We aimed to evaluate the incidence of CNS relapse as first treatment failure event and the effect of the induction chemotherapy regimen, central nervous system ‐ international prognostic index (CNS‐IPI) and other clinical and laboratory variables on the risk of CNS relapse in 564 PMLBCL patients treated with immunochemotherapy. Only 17 patients (3.0%) received CNS prophylaxis. During a 55‐month median follow‐up only 8 patients experienced CNS relapse as first event, always isolated. The 2‐year cumulative incidence of CNS relapse (CI‐CNSR) was 1.47% and remained unchanged thereafter. The CI‐CNSR was not affected by the chemotherapy regimen (R‐CHOP or R‐da‐EPOCH). None of the established International Prognostic Index factors for aggressive lymphomas predicted CNS relapse in PMLBCL. The 2‐year CI‐CNSR in patients with versus without kidney involvement was 13.3% versus 0.96% (p < 0.001); 14.3% versus 1.13% with versus without adrenal involvement (p < 0.001); and 10.2% versus 0.97% with versus without either kidney or adrenal involvement. CNS‐IPI was also predictive (2‐year CI‐CNSR in high‐risk vs. intermediate/low‐risk: 10.37% vs. 0.84%, p < 0.001). However, this association may be driven mainly by kidney and/or adrenal involvement. In conclusion, in PMLBCL, CNS relapse is rare and appears to be strongly associated with kidney and/or adrenal involvement. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. Myeloproliferative Neoplasms and Aspirin: Does Increased Platelet Turnover Matter?

Author

Göktürk, Ilgın Koçak, Özünal, Işıl Erdoğan, Göktürk, Alican, Kaya, Ali Hakan, Yılmaz, Güven, Akay, Olga Meltem, and Öztürk, Erman

Subjects
DRUG efficacy, BLOOD platelet aggregation, HYDROXYUREA, MYELOPROLIFERATIVE neoplasms, ASPIRIN, PLATELET count, RESEARCH funding, PLATELET aggregation inhibitors, DESCRIPTIVE statistics, TUMORS, THROMBOXANES, ARACHIDONIC acid, DATA analysis software, PHARMACODYNAMICS, EVALUATION
Abstract

Copyright of Turkish Journal of Hematology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2023
Full Text
View/download PDF

27. An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy

Author

Sevindik, Ömür Gökmen, Özkurt, Zübeyde Nur, Boğa, Can, Kalayoğlu Beşışık, Sevgi, İpek, Yıldız, Gedük, Ayfer, Harmandalı, Aybüke, Salihoğlu, Ayşe, Haydaroğlu Şahin, Handan, Sönmez, Mehmet, Vural, Filiz, Akay, Olga Meltem, Kurt Yüksel, Meltem, Maral, Senem, Ekinci, Ömer, Kırkızlar, Hakkı Onur, Tekinalp, Atakan, Demir, Nazlı, Merter, Mustafa, Saydam, Güray, Alacacıoğlu, İnci, Yeğin, Zeynep Arzu, Kasar, Mutlu, Mastanzade, Metban, and Özsan, Güner Hayri

Subjects
Turkish Myeloma Registry, Lines of Therapy, Interim Analysis
Abstract

Background To investigate the demographics and treatment details of the myeloma patients who were diagnosed and followed up in Turkey and received up to two lines of therapy. Methods Patients who were recorded on the database of Turkish Myeloma Registry project were included in this study if they had only received one or two lines of therapy. Demographics, patient, and disease related parameters both at the time of diagnosis and at the follow up and treatment outcomes were presented.

Published
2021

29. An Interim Analysis of the Turkish Myeloma Registry Among the Patients Who Have Received up to Two Lines of Therapy

Author

Sevindik, Omur Gokmen, primary, Ozkurt, Zubeyde Nur, additional, Boga, Can, additional, Besisik, Sevgi Kalayoglu, additional, Ipek, Yildiz, additional, Geduk, Ayfer, additional, Harmandali, Aybuke, additional, Salihoglu, Ayse, additional, Sahin, Handan haydaroglu, additional, Sönmez, Mehmet, additional, Vural, Filiz, additional, Akay, Olga Meltem, additional, Kurt Yuksel, Meltem, additional, Maral, Senem, additional, Ekinci, Omer, additional, Kirkizlar, Onur Hakki, additional, Tekinalp, Atakan, additional, Demir, Nazli, additional, Merter, Mustafa, additional, Saydam, Guray, additional, Alacacıoğlu, İnci, additional, Yegin, Zeynep Arzu, additional, Kasar, Mutlu, additional, Mastanzade, Metban, additional, and Ozsan, Guner Hayri, additional

Published
2021
Full Text
View/download PDF

30. Does Immunohistochemically CD5 Positivity Matter In Diffuse Large B-Cell Lymphoma Patients? Turkish Multicenter Study

Author

Demirci, Ufuk, primary, Kırkızlar, Hakkı Onur, additional, Ümit, Elif Gülsüm, additional, Gürsoy, Vildan, additional, Pınar, İbrahim Ethem, additional, Özkalemkaş, Fahir, additional, Güven, Zeynep Tuğba, additional, Kaynar, Leylagür, additional, Karadağ, Fatma Keklik, additional, Saydam, Güray, additional, Ekinci, Ömer, additional, Merter, Mustafa, additional, Aras, Merih Reis, additional, Albayrak, Mustafa, additional, Gülsaran, Sedanur Karaman, additional, Baş, Volkan, additional, Aydın, Berrin Balık, additional, Beköz, Hüseyin Saffet, additional, Can, Ferda, additional, D, İmdat, additional, Mehtap, Özgür, additional, Öztürk, Erman, additional, Şimşek, Bengü Çöbanoğlu, additional, Yıldırım, Murat, additional, Aylı, Meltem, additional, Ataş, Ünal, additional, Salim, Ozan, additional, Ayer, Mesut, additional, Ateşoğlu, Elif Birtaş, additional, Akay, Olga Meltem, additional, Yüksel, Meltem Kurt, additional, Paydaş, Semra, additional, Korkmaz, Selçuk, additional, Puyan, Fulya Öz, additional, and Demir, Ahmet Muzaffer, additional

Published
2021
Full Text
View/download PDF

31. P-125: An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy

Author

Sevindik, Omur Gokmen, primary, Özkurt, Zübeyde Nur, additional, Boğa, Can, additional, Besisik, Sevgi Kalayoglu, additional, Ipek, Yıldız, additional, Gedük, Ayfer, additional, Harmandalı, Aybüke, additional, Salihoğlu, Ayşe, additional, Şahin, Handan Haydaroğlu, additional, Sönmez, Mehmet, additional, Vural, Filiz, additional, Akay, Olga Meltem, additional, Yüksel, Meltem Kurt, additional, Maral, Senem, additional, Ekinci, Ömer, additional, Kırkızlar, Hakkı Onur, additional, Tekinalp, Atakan, additional, Demir, Nazlı, additional, Merter, Mustafa, additional, Saydam, Güray, additional, Alacacioğlu, inci, additional, Yeğin, Zeynep Arzu, additional, Kasar, Mutlu, additional, Mastanzade, Metban, additional, and Özsan, Güner Hayri, additional

Published
2021
Full Text
View/download PDF

32. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients

Author

Uncu Ulu, Bahar, primary, Dal, Mehmet Sinan, additional, Yönal Hindilerden, İpek, additional, Akay, Olga Meltem, additional, Mehtap, Özgür, additional, Büyükkurt, Nurhilal, additional, Hindilerden, Fehmi, additional, Güneş, Ahmet Kürşad, additional, Yiğenoğlu, Tuğçe Nur, additional, Başcı, Semih, additional, Kızıl Çakar, Merih, additional, Yanardağ Açık, Didar, additional, Korkmaz, Serdal, additional, Ulaş, Turgay, additional, Özet, Gülsüm, additional, Ferhanoğlu, Burhan, additional, Nalçacı, Meliha, additional, and Altuntaş, Fevzi, additional

Published
2021
Full Text
View/download PDF

33. HL-007: Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study

Author

Ozbalak, Murat, primary, Akay, Olga Meltem, additional, Pehlivan, Mustafa, additional, Yildiz, Birol, additional, Uzay, Ant, additional, Yigenoglu, Tugce Nur, additional, Elverdi, Tugrul, additional, Kaynar, Leylagul, additional, Ayyildiz, Orhan, additional, Hindilerden, Ipek Yonal, additional, Goksoy, Hasan Sami, additional, Guner, Sebnem Izmir, additional, Gunes, Ahmet Kursad, additional, Sonmez, Mehmet, additional, Yuksel, Meltem Kurt, additional, Bozdag, Sinem Civriz, additional, Ozkurt, Zubeyde Nur, additional, Toptas, Tayfur, additional, Dogu, Mehmet Hilmi, additional, Salim, Ozan, additional, Saydam, Guray, additional, Yavasoglu, Irfan, additional, Ayli, Meltem, additional, Ozet, Gulsum, additional, Albayrak, Murat, additional, Atesoglu, Elif Birtas, additional, Toprak, Selami K., additional, Yildirim, Rahsan, additional, Mehtap, Ozgur, additional, Besisik, Sevgi Kalayoglu, additional, Nalcaci, Meliha, additional, Altuntas, Fevzi, additional, and Ferhanoglu, Burhan, additional

Published
2021
Full Text
View/download PDF

34. Poster: HL-007: Brentuximab Vedotin Consolidation Therapy after Autologous Stem-Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma: Multi-Center Retrospective Study

Author

Ozbalak, Murat, primary, Akay, Olga Meltem, additional, Pehlivan, Mustafa, additional, Yildiz, Birol, additional, Uzay, Ant, additional, Yigenoglu, Tugce Nur, additional, Elverdi, Tugrul, additional, Kaynar, Leylagul, additional, Ayyildiz, Orhan, additional, Hindilerden, Ipek Yonal, additional, Goksoy, Hasan Sami, additional, Guner, Sebnem Izmir, additional, Gunes, Ahmet Kursad, additional, Sonmez, Mehmet, additional, Yuksel, Meltem Kurt, additional, Bozdag, Sinem Civriz, additional, Ozkurt, Zubeyde Nur, additional, Toptas, Tayfur, additional, Dogu, Mehmet Hilmi, additional, Salim, Ozan, additional, Saydam, Guray, additional, Yavasoglu, Irfan, additional, Ayli, Meltem, additional, Ozet, Gulsum, additional, Albayrak, Murat, additional, Atesoglu, Elif Birtas, additional, Toprak, Selami K., additional, Yildirim, Rahsan, additional, Mehtap, Ozgur, additional, Besisik, Sevgi Kalayoglu, additional, Nalcaci, Meliha, additional, Altuntas, Fevzi, additional, and Ferhanoglu, Burhan, additional

Published
2021
Full Text
View/download PDF

35. A 52-Year-Old Man With Progressive Weakness and Incontinence

Author

Altintas, Ayse, primary, Danyeli, Ayca Ersen, additional, Bozkurt, Subutay Berke, additional, Uysal, Sanem Pinar, additional, Akpek, Sergin, additional, Aygun, Murat Serhat, additional, Akay, Olga Meltem, additional, Kahyaoglu, Bulent, additional, Peker, Selcuk, additional, Ure, Umit Barbaros, additional, and Ferhanoglu, Burhan, additional

Published
2021
Full Text
View/download PDF

41. Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study

Author

Akay, Olga Meltem, primary, Ozbalak, Murat, additional, Pehlivan, Mustafa, additional, Yildiz, Birol, additional, Uzay, Ant, additional, Yigenoglu, Tugce Nur, additional, Elverdi, Tugrul, additional, Kaynar, Leylagul, additional, Ayyildiz, Orhan, additional, Yonal Hindilerden, Ipek, additional, Goksoy, Hasan Sami, additional, Izmir Guner, Sebnem, additional, Gunes, Ahmet Kursad, additional, Sonmez, Mehmet, additional, Kurt Yuksel, Meltem, additional, Civriz Bozdag, Sinem, additional, Ozkurt, Zubeyde Nur, additional, Toptas, Tayfur, additional, Dogu, Mehmet Hilmi, additional, Salim, Ozan, additional, Saydam, Guray, additional, Yavasoglu, Irfan, additional, Ayli, Meltem, additional, Ozet, Gulsum, additional, Albayrak, Murat, additional, Birtas Atesoglu, Elif, additional, Toprak, Selami K., additional, Yildirim, Rahsan, additional, Mehtap, Ozgur, additional, Kalayoglu Besisik, Sevgi, additional, Nalcaci, Meliha, additional, Altuntas, Fevzi, additional, and Ferhanoglu, Burhan, additional

Published
2021
Full Text
View/download PDF

43. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.

Author

Uncu Ulu, Bahar, Dal, Mehmet Sinan, Yönal Hindilerden, İpek, Akay, Olga Meltem, Mehtap, Özgür, Büyükkurt, Nurhilal, Hindilerden, Fehmi, Güneş, Ahmet Kürşad, Yiğenoğlu, Tuğçe Nur, Başcı, Semih, Kızıl Çakar, Merih, Yanardağ Açık, Didar, Korkmaz, Serdal, Ulaş, Turgay, Özet, Gülsüm, Ferhanoğlu, Burhan, Nalçacı, Meliha, and Altuntaş, Fevzi

Published
2022
Full Text
View/download PDF

47. OKHN UYGULANMIŞ YÜKSEK RİSKLİ HL’DE BRENTUKSİMABVEDOTİN KONSOLİDASYONU GERÇEK YAŞAM VERİLERİ:ÇOK MERKEZLİ ÇALIŞMA

Author

GÖKER, HAKAN, FERHANOĞLU, AHMET BURHAN, ALTUNTAŞ, FEVZİ, NALÇACI, MELİHA, YILDIRIM, RAHŞAN, TOPRAK, SELAMİ KOÇAK, BİRTAŞ ATEŞOĞLU, ELİF, ALBAYRAK, MURAT, TOPTAŞ, TAYFUR, ÖZET, GÜLSÜM, AYLI, MELTEM, YAVAŞOĞLU, İRFAN, SALİM, OZAN, ELVERDİ, TUĞRUL, DOĞU, MEHMET HİLMİ, KAYNAR, LEYLAGÜL, AYYILDIZ, MEHMET ORHAN, YÜKSEL, MELTEM, SÖNMEZ, MEHMET, GÜNEŞ, AHMET KÜRŞAD, İZMİR GÜNER, ŞEBNEM, GÖKSOY, HASAN SAMİ, YÖNAL HİNDİLERDEN, İPEK, UZAY, ANT, YİĞENOĞLU, TUĞÇE, PEHLİVAN, MUSTAFA, YILDIZ, BİROL, ÖZBALAK, MUSTAFA MURAT, AKAY, OLGA MELTEM, and ÖZKURT, ZÜBEYDE NUR

Published
2020

48. An Anomaly with Potential as a New Prognostic Marker in CLL with del(13q): Gain of 16p13.3.

Author

Isik, Sevgi, Gunden, Gulcin, Gunduz, Eren, Akay, Olga Meltem, Aslan, Abdulvahap, Ozen, Hulya, Cilingir, Oguz, Erzurumluoglu Gokalp, Ebru, Kocagil, Sinem, Artan, Sevilhan, Gulbas, Zafer, and Durak Aras, Beyhan

Subjects
PROGNOSIS, CHRONIC lymphocytic leukemia, TUMOR classification, THERAPEUTICS
Abstract

Deletion 13q [del(13q)] is a favorable prognostic marker if it is detected as a sole abnormality in chronic lymphocytic leukemia (CLL). However the clinical courses of cases with isolated del(13q) are quite heterogeneous. In our study, we investigated copy number variations (CNVs), loss of heterozygosity (LOH), and the size of del(13q) in 30 CLL patients with isolated del(13q). We used CGH+SNP microarrays in order to understand the cause of this clinical heterogeneity. We detected del(13q) in 28/30 CLL cases. The size of the deletion varied from 0.34 to 28.81 Mb, and there was no clinical effect of the deletion size. We found new prognostic markers, especially the gain of 16p13.3. These markers have statistically significant associations with short time to first treatment and advanced disease stage. Detecting both CNVs and LOH at the same time is an advantageous feature of aCGH+SNP. However, it is very challenging for the array analysis to detect mosaic anomalies. Therefore, it is very important to confirm the results by FISH. In our study, we detected approximately 9% mosaic del(13q) by microarray. In addition, the gain of 16p13.3 may affect the disease prognosis in CLL. However, additional studies with more patients are needed to confirm these results. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results